Articles tagged with Sars Cov 2
Researchers identified compounds that target VPS34 and fatty acid metabolism as potent inhibitors of SARS-CoV-2 replication. These findings reveal critical pathways involved in the virus's life cycle, providing novel insights for developing therapeutics targeting these pathways.
A recent study by University of Wyoming economists suggests that public health messages focusing on the personal health benefits of COVID-19 vaccines are most effective in increasing vaccination intentions. The researchers found that such messages increased intended vaccinations by 16 percentage points, significantly more than other ty...
Researchers have created an 'atlas' charting how antibodies attack the spike protein of SARS-CoV-2, identifying broadly responsive neutralizers and regions resistant to attack. The study highlights the importance of studying antibody responses for developing effective COVID-19 booster vaccines.
The article highlights the advantages of intranasal vaccination against SARS-CoV-2, including needle-free administration and elicitation of mucosal immunity in the respiratory tract. Researchers argue that this approach may be more effective than traditional intramuscular vaccinations, offering a broader range of protection.
The authors argue that intranasal COVID-19 vaccines could provide additional layers of protection by eliciting immunoglobulin A and resident memory cells in the nasal passages. An ideal vaccination strategy may consist of an intramuscular vaccine combined with an intranasal booster, offering a dual approach to combat respiratory viruses.
A study investigated longitudinal serological and vaccination responses to SARS-COV-2 in dental professionals. The results showed that natural infection with SARS-COV-2 leads to persistent, neutralizing and protective serological responses in over 70% of participants.
Researchers develop open-source molecular detection method to track B.1.1.7 (Alpha) variant in wastewater, providing actionable community-level information for health authorities. The breakthrough expands utility of wastewater surveillance beyond SARS-CoV-2 testing.
The study found that two-dose mRNA vaccines provided 88% protection against the original SARS-CoV-2 virus, 86% against the Alpha variant, and 77% against the Beta variant. Previous SARS-CoV-2 infection also conferred similar protection to mRNA vaccination.
Scientists at Goethe University have identified 15 short segments of the SARS-CoV-2 genome that are highly conserved across various coronaviruses and perform essential regulatory functions. These segments were found to be resistant to mutations, making them promising targets for developing new drugs against SARS-CoV-2.
A study published in Nature Communications found that COVID-19 antibody levels remain high for at least nine months after infection, regardless of symptoms. The research tested over 85% of an Italian town's residents and found no significant difference between symptomatic and asymptomatic cases.
Researchers at the University of Bern created an in vitro cell culture model biobank from 12 different animal species to assess their susceptibility to SARS-CoV-2 infection. The study found that rhesus macaques and cats may be particularly vulnerable, highlighting the need for close surveillance and early detection programs.
The L452R mutation of the SARS-CoV-2 spike protein evades human immune response via HLA-A24, a common allele in East/Southeast Asian populations. This mutation also enhances viral infectivity and replication efficiency.
A novel coronavirus related to Covid-19 has been found in UK horseshoe bats, with the team suggesting that these bats have likely harbored the virus for thousands of years. The discovery highlights the need for robust genotype testing in bat populations and raises concerns about the potential for viral mutation.
Researchers created a stem cell model demonstrating SARS-CoV-2's entry into the human brain through blood vessels and infected pericytes. Astrocytes were the main target of this secondary infection, leading to complications like inflammation, clotting, stroke, or hemorrhages.
A new COVID-19 vaccine candidate has shown effectiveness in inducing both neutralizing antibodies and CD8+ T cells, potentially reducing disease transmission. The vaccine combines yeast-expression technology and a novel adjuvant formulation, making it suitable for large-scale production and cost-effective distribution.
This study analyzed circumstances of SARS-CoV-2 infection in France, identifying key risk factors and behaviors associated with higher infection rates. The study found that working professionals, car-sharing, recent travel abroad, and visits to bars, restaurants, and gyms increased the risk of infection.
A rapid method to quantify antibodies against SARS-CoV-2 has been developed by scientists at Hokkaido University. The test is highly accurate, quick, and easy to perform, requiring only 20 minutes to complete.
A new protein-based vaccine candidate combined with a potent adjuvant has shown effective protection against SARS-CoV-2 in animal studies. The combination improved antibody and T cell responses, reducing viral load and inflammation.
A lack of genomic sequencing impedes the global response to the COVID-19 pandemic. The US ranks 33rd in variant surveillance, highlighting the need for improved international sequencing efforts to track and respond to new SARS-CoV-2 variants. Enhanced sequencing is crucial for understanding disease transmission and severity.
A new study published in the Journal of Exposure Science and Environmental Epidemiology found a significant association between wildfire smoke exposure and an increased risk of contracting COVID-19 in Reno, Nev. During a prolonged 2020 wildfire smoke event, PM2.5 levels were associated with a 17.7% rise in COVID-19 cases.
Researchers at the University of Fukui found that short chain fatty acids can suppress ACE2 expression in nasal epithelial cells, reducing SARS-CoV-2 transmission. The study suggests potential therapeutic applications against COVID-19 and could aid in the fight against the virus.
Researchers at the University of Nebraska-Lincoln discovered that SARS-CoV-2 mutations occur in predictable locations, similar to its closest relatives. This finding helps inform predictions of how the virus will continue to evolve and could aid in developing effective vaccines.
A recent study in Annals of Internal Medicine suggests that mandatory COVID-19 vaccination for healthcare workers is strongly justified due to the higher mortality rate of SARS-CoV-2 compared to influenza. The authors propose strategies to increase employee acceptance and overcome vaccine hesitancy, emphasizing the importance of protec...
A study reveals that highly mutated SARS-CoV-2 can emerge in people living with advanced HIV if they cannot clear the virus through effective antiretroviral therapy. This increases the risk of severe disease and potentially more potent variants.
A study in Switzerland found that people living in poorer neighborhoods were less likely to be tested for COVID-19, but more likely to test positive, be hospitalized, or die compared to those in wealthier areas. The study also found stronger associations between neighborhood socioeconomic position and outcomes in younger age groups.
A recent study published in JAMA Oncology found that the Pfizer-BioNTech vaccine appears to be safe and effective in patients with cancer, achieving satisfactory serologic status. Despite a lag in antibody production compared to non-cancer control groups, most patients experienced seroconversion after the second dose.
A new study reveals CoronaVac vaccine antibodies are less effective against the P.1 Brazil variant, raising concerns about vaccination program effectiveness and potential reinfection of previously infected individuals.
A new study published in Emerging Infectious Diseases found that mathematical models informed early statewide policies in Colorado, avoiding 97% of potential hospitalizations. The modeling team developed a SEIR model calibrated to Colorado COVID-19 data and provided real-time estimates to policymakers.
Researchers at Penn State designed a synthetic defective SARS-CoV-2 virus that interferes with the real virus's growth, potentially causing its extinction. The therapeutic may be used as a self-promoting antiviral treatment for COVID-19.
The study found that APOBEC4 is highly expressed in cells and tissues attacked by SARS-CoV-2, such as epithelial cells in the lungs and gastrointestinal tract. This knowledge could lead to characterizing antiviral cell status attributed to AID/APOBECs specific to patients and correlating it with organ damage and COVID-19 severity.
A study has identified a microRNA-like small RNA encoded by SARS-CoV-2 as a reliable biomarker for stratifying severe COVID-19 patients from mild/moderate ones. This biomarker enables early detection of high-risk individuals, allowing for optimized treatment and improved treatment outcomes.
This study found SARS-CoV-2 seroprevalence to be high in Lombardy region healthcare workers, with certain categories and facilities at higher risk of infection. The study also identified operational units, such as in-hospital wards and outpatient facilities, as key risk factors for SARS-CoV-2 infection.
A new international study found that laboratory-developed protein spikes consistent with COVID-19 virus are highly similar, providing reassurance for vaccine design and antibody testing. The study used glycan coatings to mimic the infectious virus and showed consistent results across five laboratories worldwide.
Scientists have identified stable T cell vaccine targets in SARS-CoV-2, offering long-lasting protection against multiple variants. The approach, developed for HIV, uses structure-based network analysis to identify mutationally constrained epitopes that can be recognized by immune cells.
Researchers found that animal models infected with SARS-CoV-2 treated with a deuterated protease inhibitor had significantly increased survival and decreased lung viral load. The results suggest that postinfection treatment with inhibitors of proteases essential for viral replication may be an effective treatment against SARS-CoV-2.
Researchers at La Jolla Institute for Immunology found that people who recovered from COVID-19 or received Moderna or Pfizer-BioNTech vaccines have cross-reactive T cells that can target several SARS-CoV-2 variants. This reactivity is key to the body's immune response, allowing it to kill infected cells and stop severe infections.
Scientists at the Francis Crick Institute and University of Dundee have identified 15 molecules that inhibit SARS-CoV-2 replication by blocking different enzymes. Three of the molecules are existing drugs with known safety data, which could be developed into new COVID-19 treatments quickly.
Researchers identified that multiciliated cells in the nasal epithelium are the first cells targeted by SARS-CoV-2 in early COVID-19 infection. These cells serve as the main factories for mass-producing viruses, highlighting the potential for targeting these cells using specific treatments to curb infections.
The team's real-world results demonstrate the potential of SwabSeq to be used for population-wide testing on an unprecedented scale. The test has shown extremely high sensitivity and specificity, making it a promising solution for scaling up COVID-19 testing.
Researchers found that people with milder COVID-19 symptoms tend to have more killer T cells that recognize peptides shared with other coronaviruses, indicating a previous encounter. This may help explain why some individuals are more resilient to infection and potentially predict severe symptoms.
Researchers at the University of Melbourne found that liquid chalk is effective against both SARS-CoV-2 and influenza A viruses. The study tested four different types of chalk, with three working incredibly effectively, and showed complete resistance to norovirus in some cases.
A team of researchers developed a high-throughput biochemical assay to assess small molecule impact on SARS-CoV-2 nonstructural protein 14, identifying potential inhibitors from FDA-approved drugs. The study aims to deliver therapeutics for the SARS-CoV-2 virus, targeting its critical methyltransferase activity.
Researchers found that vaccinated individuals have a lower viral load, shorter infection time and milder symptoms than unvaccinated people. The study also showed a significant reduction in the risk of having COVID-19 with an accompanying fever.
A Duke-led team identified how multiple mutations on the SARS-CoV-2 spike protein create variants that are more transmissible and resistant to antibodies. The researchers found that different variant spikes use distinct mechanisms to achieve this, raising concerns about the effectiveness of current vaccines.
A recent study found that women previously infected with COVID-19 have similar ovarian reserve and fertility treatment outcomes compared to those without a history of the virus. The study monitored hormone levels in 46 patients undergoing IVF in Spain between May and June 2020, revealing no variation in anti-Mullerian hormone (AMH) lev...
Research reveals that the deletion of two amino acids in the spike protein makes the virus twice as infective, allowing it to replicate efficiently despite other mutations. This mutation has been found globally, particularly in Europe, Africa, and Asia, and may explain its widespread spread.
Researchers have developed wearable biosensors that can be integrated into standard face masks to detect SARS-CoV-2 and other pathogens. The technology, called wFDCF, involves synthetic biology reactions embedded in fabrics, providing rapid detection with accuracy comparable to PCR tests.
A new UC Davis study confirms that SARS-CoV-2 contamination on hospital surfaces is unlikely to be infectious. The research used genome sequencing to detect the virus on surfaces and found that only a small percentage of samples were positive, suggesting that improved cleaning protocols may have reduced transmission.
Researchers at WashU Medicine discovered a single mutation in SARS-CoV-2 that allows the virus to enter human lung cells through an alternative route, which may evade COVID-19 antibodies or vaccines. The study suggests the virus can change and adapt in unexpected ways to cause infection.
A recent study using computer modelling found that the SARS-CoV-2 virus binds more tightly to human cells than any other tested animal species, including bats and pangolins. The results suggest that the virus may have adapted to become an effective human pathogen through convergent evolution or genetic recombination.
A single dose of either the Pfizer or Astra Zeneca COVID-19 vaccine offers around 60% protection against infection from SARS-CoV-2 in residents of long-term care facilities aged 65 and over. Vaccination also reduces the risk of transmission and infectivity, with a protective effect evident from 4 weeks after vaccination.
Researchers analyzed 7,548 SARS-CoV-2 genomes to find associations between genomic variants and patient deaths. They identified a key mutation linked to changes in the viral spike protein, which plays a crucial role in viral entry.
Researchers at Karolinska Institutet have developed a cost-effective method for detecting new coronavirus variants. The COVseq technology uses multiplex PCR and pooling to sequence thousands of viral genomes per week, making it an affordable solution for global surveillance.
A new study by NYU Langone Health researchers discovered a molecular mechanism hijacked by SARS-CoV-2 that makes it vulnerable to drug candidates. The study showed that coronavirus reproduction requires chemical changes made by the human protein METTL3, which can be inhibited by the compound STM2457.
Researchers used genome-wide association studies (GWAS) to analyze whole-genome sequencing data of SARS-CoV-2 mutations and COVID-19 mortality data. They identified a mutation in the spike protein linked to increased mortality, which was later found to be part of the P.1 variant.
Researchers found no association in SARS-CoV-2 positivity rates between healthcare workers wearing respirator masks and those wearing medical masks. The study suggests that mask utilization is not a significant factor in preventing SARS-CoV-2 transmission among healthcare workers.
Researchers developed two groups of molecules that effectively inhibit SARS-CoV-2 variants, bypassing mutations and disabling viral entry. The nanobodies recognize a conserved region of the receptor binding domain, blocking viral entry even when human antibodies cannot.
An analysis of antibodies from over 8,000 undiagnosed adults found that nearly 5% of the US population harbored SARS-CoV-2 antibodies. The highest positivity rates were among African Americans and young urban dwellers.
A new study by Martin Luther University Halle-Wittenberg found that women ran slower in the presence of spectators but performed better in shooting than men. This challenges the social facilitation theory and suggests a gender-specific difference in response to audiences or lack thereof.
The Vigilant platform combines reverse transcription-recombinase polymerase amplification (RT-RPA) with bacterial enzymes to detect SARS-CoV-2 gene sequences. This method produces comparably reliable results as PCR tests but is cheaper and easier to use, making it suitable for non-laboratory settings.